Anivive Bags NIAID Contract Worth Up to USD 33 Million to Progress Valley Fever Vaccine
Anivive Lifesciences Inc. has announced that the National Institute of Allergy and Infectious Diseases (NIAID) has awarded Anivive a new contract worth up to USD 33 million to support the development of a vaccine against the fungus Coccidioides, which causes Valley Fever.
Valley Fever Vaccine | 03/08/2024 | By Aishwarya | 241
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy